Please assess the completion status of the following clinical trial:

Trial Title: Tailored Operative or Non-operative Management for Low-risk Rectal Cancer After Intensive Neoadjuvant Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years and ≤85 years~* ECOG Performance status 0-1~* Histologically confirmed diagnosis of adenocarcinoma of the rectum, with tumor differentiation Grade 1-3~* The distance from down verge of tumor to anal-rectal junction (ARJ) ≤8cm based on MRI, or ≤12cm based on sigmoidoscopy;~* Clinical Stage T2 or T3a or T3b and EMVI (-) and MRF (-) and extra-mesorectal metastatic lymph node (-) based on MRI~* No evidence of distant metastases~* No prior pelvic radiation therapy~* No prior chemotherapy or surgery for rectal cancer~* No active infections requiring systemic antibiotic treatment~* ANC \> 1.5 cells/mm3, HGB \> 10.0 g/dL, PLT \> 100,000/mm3, total bilirubin ≤ 1.5 x ULN, AST≤ 3 x ULN, ALT ≤ 3 x ULN.~* Patients must read, agree to, and sign a statement of Informed Consent prior to participation in this study.~Exclusion Criteria:~* Recurrent rectal cancer~* Primary unresectable rectal cancer. A tumor is considered unresectable when invading adjacent organs and an en-bloc resection will not achieve negative margins.~* Creatinine level greater than 1.5 times the upper limit of normal.~* Patients who have received prior pelvic radiotherapy.~* Patients who are unable to undergo an MRI.~* Patients with a history of a prior malignancy within the past 5 years, except for well treated basal cell cancer, squamous cell skin cancer, breast cancer, thyroid cancer or small renal cancer, and with DFS \>5 years.~* Patients with a history of any arterial thrombotic event within the past 6 months. This includes angina (stable or unstable), MI, TIA, or CVA.~* Other Anticancer or Experimental Therapy.~* Women who are pregnant or breast-feeding.~* Patients with any other concurrent medical or psychiatric condition or disease which would make them inappropriate candidates for entry into this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Group A:Clinical complete response (cCR) (Type: None): Patients who achieve cCR when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation CapeOX(Capecitabine+Oxaliplatin) will receive Nonoperative Management(NOM).
- Group B:Near-cCR (Type: None): Patients who achieve near-cCR when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation CapeOX(Capecitabine+Oxaliplatin) will receive Local Excision(LE) or Nonoperative Management(NOM).
- Group C:Residual tumor (Type: None): Patients with residual tumor when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation CapeOX(Capecitabine+Oxaliplatin) will receive Total Mesorectal Excision(TME).

Based on this trial design, predict the completion outcome and termination type (if applicable).